Form 4: Adial Pharmaceuticals Director Kevin Schuyler Acquires Stock Options

Director Kevin Schuyler acquired stock options in Adial Pharmaceuticals, Inc. on March 25, 2024.

Summary

• On March 25, 2024, Kevin Schuyler, a director of Adial Pharmaceuticals, Inc., acquired 12,000 stock options with an exercise price of $1.35.
• The options vest pro rata on a monthly basis over 36 months, starting April 25, 2024.
• The options expire on March 24, 2034.
• Following the transaction, Schuyler directly owns 12,000 derivative securities.

Sentiment

Score: 5

Explanation: The document is a neutral regulatory filing. The acquisition of options by a director could be interpreted as mildly positive, but the filing itself is simply a disclosure of the transaction.

Positives

• The acquisition of stock options by a director could be seen as a positive sign, indicating confidence in the company's future prospects.

Industry Context

This is a standard SEC Form 4 filing, reflecting a change in beneficial ownership by a company insider. Such filings are common and provide transparency into insider transactions.

Stakeholder Impact

• Shareholders are informed about insider transactions, which can influence their perception of the company's prospects.

Key Dates

Keywords

stock options, director, acquisition, ADIL, Adial Pharmaceuticals, Form 4, insider trading